$IOVA News

Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026

Iovance Biotherapeutics Reports Deep, Durable Responses With Lifileucel Monotherapy In Metastatic UPS And DDLPS At ESMO 2026

Iovance’s Melanoma Therapy Shows Promising 4-Year Data – Retail Says Acquisition Imminent Before 2027-End

Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced Melanoma

Iovance's Phase 2 Lifileucel Plus Pembrolizumab Delivers 62.5% ORR And 29.2% Complete Response Rate In Frontline Advanced Melanoma, With Median OS Not Yet Reached At 50.9 Months

Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $18

Baird Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $11

Transcript: Iovance Biotherapeutics Q2 2026 Earnings Conference Call

Iovance: Buy Now Before Many Growth Catalysts Kick In

Why Iovance Biotherapeutics (IOVA) Effortlessly Soared 256% in Q3

Iovance Biotherapeutics (IOVA) Stock Gets Fair Value Boost On Amtagvi Demand And Margin Outlook

Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

Wells Fargo Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $18

Iovance Biotherapeutics Stock Pauses After Hitting New 52-Week High: What's Going On?

Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains?

Iovance Biotherapeutics (IOVA) Eyes 60% Revenue Growth, Shares Jump 31%

Iovance: The Turnaround Is Priced In, Downgrading To Hold

Iovance Stock Surges as Strong Melanoma Drug Demand Drives Growth